Cibrim-Z is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Pharmacology: Fluoro photometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Indications
Cibrim-Z is indicated for lowering intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Dosage
The recommended dose is one drop of Cibrim-Z in the affected eye (s) three times daily, approximately 8 hours apart. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
Contraindications
Cibrim-Z is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.
Precautions
Pregnancy: Category C.
Cibrim-Z should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
Lactation:
It is not known whether Cibrim-Z is excreted in human milk, although in animal studies, brimonidine tartrate has been shown to be excreted in breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use:
Brimonidine tartrate ophthalmic solution is not recommended in paediatric patients below the age of 2 years.
Geriatric Use:
No overall differences in safety or effectiveness have been observed between elderly and other adult patients.